COVID-19 drug repurposing: Summary statistics on current clinical trials
and promising untested candidates
Abstract
Repurposing of existing antiviral drugs, immunological modulators, and
supportive therapies represents a promising path toward rapidly
developing new control strategies to mitigate the devastating public
health consequences of the COVID-19 pandemic. A comprehensive
text-mining and manual curation approach was used to comb and summarize
the most pertinent information from existing clinical trials. Drugs with
previous efficacy against related betacoronaviruses like SARS and MERS
were also systematically evaluated as potentially promising candidates
for drug repositioning.24 Apr 2020Submitted to Transboundary and Emerging Diseases 27 Apr 2020Submission Checks Completed
27 Apr 2020Assigned to Editor
28 Apr 2020Reviewer(s) Assigned
13 Jun 2020Review(s) Completed, Editorial Evaluation Pending
14 Jun 2020Editorial Decision: Revise Minor
18 Jun 20201st Revision Received
20 Jun 2020Submission Checks Completed
20 Jun 2020Assigned to Editor
25 Jun 2020Review(s) Completed, Editorial Evaluation Pending
25 Jun 2020Editorial Decision: Accept
